Objective: To explore the efficacy of vonoprazan fumarate in the treatment of laryngopharyngeal reflux disease（LPRD） evaluated by the Chinese version of the RSS-12 scale. Methods:A total of 100 LPRD patients treated in the otolaryngology-head and neck surgery outpatient clinic of our hospital were randomly divided into two groups（50 cases each）. The observation group was treated with vonoprazan fumarate（20 mg, once daily）, and the control group was treated with esomeprazole enteric-coated capsules（20 mg, twice daily） for 12 weeks. The selected observation indicators in this study included RSI, the Chinese version of RSS-12, and RFS scores before and after treatment. Results:Prior to treatment, there was no statistically significant difference in the Chinese version of RSS-12, RSI, and RFS between the two groups（P>0.05）. After 8 and 12 weeks of antacid treatment, both the Chinese version of RSS-12 and RSI significantly decreased in both group （P<0.05）. The changes in symptoms were particularly noticeable between 0-8 weeks of treatment according to the Chinese version of RSS-12 and RSI. After 12 weeks of treatment, the RFS scores significantly decreased compared to pretreatment levels （P<0.05）. After 12 weeks of antacid treatment, according to the Chinese version of RSS-12, 80% of patients in the observation group showed a good therapeutic response, compared to 64% in the control group; according to RSI, 90% of patients in the observation group showed a good therapeutic response, compared to 84% in the control group. There was no statistically significant difference in the treatment effect between the two groups after 12 weeks of treatment（P>0.05）. Conclusion:Vonoprazan fumarate can significantly improve the symptoms and signs of laryngopharyngeal reflux, and their treatment effect is not inferior to proton pump inhibitors. Compared with RSI, the Chinese version of RSS-12 can serve as a new screening tool for clinical diagnosis of LPRD in China.
Humans ; Sulfonamides/therapeutic use* ; Male ; Pyrroles/therapeutic use* ; Female ; Laryngopharyngeal Reflux/drug therapy* ; Treatment Outcome ; Middle Aged ; Esomeprazole/therapeutic use* ; Proton Pump Inhibitors/therapeutic use* ; Adult

OBJECTIVE: To explore the relevance between nasal symptoms and laryngopharyngeal reflux disease in patients with allergic rhinitis. METHOD: Thirty patients of laryngopharyngeal reflux disease were diagnosed in ENT outpatient department in our hospital. All patients have symptoms of sneeze, nasal discharge as chief complaint and they responded no effect for other normal treatment for nasal-sinusitis at least three months. Orally before meals, a dose of 5 mg Mosapride citrate each time, three times a day for 7 days. Orally before meals, a dose of 20 mg Esomeprazole each time, two times a. day for 2-3 months. Nasal spray, one spray of azelastine hydrochloride once, two times a day for 2 month. RESULT: Laryngopharyngeal reflux symptom scores at four time points (the first visit, post treatment 15 days, 45 days, 75 days) were analyzed by repeated measures analysis of variance. There is a significant difference in four time points. CONCLUSION Laryngopharyngeal reflux disease has a strong association with allergic rhinitis. Patients who has allergic rhinitis nasal symptoms as chief complaint must be exclude, the laryngopharyngeal reflux disease first.
Benzamides ; therapeutic use ; Esomeprazole ; therapeutic use ; Humans ; Laryngopharyngeal Reflux ; complications ; drug therapy ; Morpholines ; therapeutic use ; Phthalazines ; therapeutic use ; Pilot Projects ; Rhinitis, Allergic ; drug therapy ; etiology

OBJECTIVE: To analyze the therapeutic effect of proton pump inhibitor(PPI) on alleviation of hoarseness symptoms in patients with laryngopharyngeal reflux(LPR). METHOD: The LPR outpatients in ENT department of our hospital(60 cases)complained of hoarseness were enrolled in the study from August of 2013 to October of 2014. All of them were randomly divided into group A and B. The individuals in group A (30 cases) taked golden voice capsule to treat for 3 months, while the individuals in group B (30 cases) taked golden voice capsule and omeprazole to treat for 3 months. The data about reflux symptom index (RSI), reflux finding score (RFS) and voice handicap index (VHI)from the first month to the third month after treatment were recorded and compared group A with group B. RESULT: The scores of RSI and RFS in patients (60 cases) before treatment were significantly correlated with their VHI (r=0. 823, P<0. 01; r=0. 873, P<0. 01). The score changes of RSI and VHI from the first to the third month after treatment in group B were significantly higher than those in group A (P<0. 01). Meanwhile, the score changes of RFS from the third month after treatment in group B were significantly higher than those in group A (t=8. 307, P<. 01), but the differences were not significant for RFS from the first to the second month after treatment between group A and group B(t=1. 128, P>0. 05; t=0. 376, P> 0. 05). CONCLUSION PPI therapy could significantly alleviate the hoarseness symptom in LPR patients.
Hoarseness ; drug therapy ; Humans ; Laryngopharyngeal Reflux ; drug therapy ; Proton Pump Inhibitors ; therapeutic use

OBJECTIVETo observe the clinical curative effect of anti-reflux treatment for obstructive sleep apnea hypopnea syndrome (OSAHS) in children.

METHODSTwenty children with sleep-disordered breathing were included in this study. There were 15 males and 5 females, aged 3-9 years old, median 6 years old. The electronic laryngoscope, polysomnography (PSG) monitoring, Reflux symptom index (RSI) questionnaire and Reflux finding score (RFS) were used to establish the initial diagnosis of OSAHS with LPRD, preclude adenoid hypertrophy and tonsil hypertrophy and nasal disorders. Oral Domperidone and Omeprazole were given for treatment. For children under 3-year-old, the dosage of Domperidone was 0.6 ml.kg⁻¹.day⁻¹.For children over 3-year-old, Domperidone combined with Omeprazole were given with the dosage of 0.3 mg.kg⁻¹.day⁻¹.

RESULTSAfter 4 weeks of treatment, 19 patients symptoms of OSAHS include disturbed sleep, dyspnoea and apneic attack improved. After 8 weeks of treatment, 20 cases with OSAHS symptoms improved than before treatment. Under the electronic laryngoscope, the decrease in pharyngeal lymphoid follicles, the epiglottis, aryepiglottic fold and scoop intergenic region erythema shallow, edema lessened. After treatment of 4 weeks and 8 weeks, there was statistically significant (P < 0.05). Before and after treatment, the difference of RFS was statistically significant (P < 0.05); PSG monitoring proved significant effect in 3 cases (15.0%), effective in 11 cases (55.0%) and 6 cases were ineffective (30.0%). Twenty patients with obstructive apnea index change was not obvious (P > 0.05), apnea hypopnea index and lowest artery oxygen saturation better, differences were statistically significant (Z of 2.819 and 2.733 respectively, P < 0.05).

CONCLUSIONThe treatment of LPRD can improve the symptoms of OSAHS, these two diseases may coexist in mutual relations.

Child ; Child, Preschool ; Female ; Humans ; Laryngopharyngeal Reflux ; complications ; drug therapy ; Male ; Sleep Apnea Syndromes ; complications ; drug therapy ; Surveys and Questionnaires ; Treatment Outcome

OBJECTIVE: To investigate the diagnosis and treatment of laryngopharyngeal reflux disease. METHOD: Patients suspect of laryngopharyngeal reflux disease in our out-patient department from Jan 2008 to Jan 2009 were included in this study. All patients were assessed using the reflux symptom index(RSI) and the reflux finding score(RFS). The positive criteria of RSI was score > 13 and that of RFS was score > 7. Fifty-eight double positive patients accepted omeprazole oral administration. After continuous oral administration for three months, all patients received RSI and RFS assessment again. RESULT: After treatment, the symptoms of 41 patients were significantly alleviated. In addition, RSI were positive in 41 cases and RFS were positive in 37 cases. Thirty-seven cases were double positive. CONCLUSION The RSI and RFS could serve as an effective assessment method and could accurately document treatment efficacy in patients with LPR. Proton pump inhibitor such as omeprazole is an effective treatment for patients with LPR.
Adolescent ; Adult ; Aged ; Female ; Humans ; Laryngopharyngeal Reflux ; diagnosis ; drug therapy ; physiopathology ; Male ; Middle Aged ; Proton Pump Inhibitors ; therapeutic use ; Young Adult

OBJECTIVE: To evaluate the efficacy of proton pump inhibitor (PPI) therapy with esomeprazole on laryngopharyngeal reflux (LPR) by pepsin immunoassay in the sputum. METHOD: From June 2009 to March 2010, patients in the ENT outpatient department of Nanfang hospital with a reflux finding score (RFS) >7 and a reflux symptom index (RSI) >13 were selected. Their sputum was obtained in the morning for pepsin assay. Twenty-six patients with positive results of pepsin assay were enrolled and received esomeprazole 20 mg twice daily for two months. They paid return visits every two weeks. RSI, RFS and pepsin concentration in the sputum were assessed at baseline and after two months. Pepsin in the sputum was measured by enzyme linked immunoadsorbent assay. RESULT: After 8 weeks, 24 patients got symptom improvements except 2. All got improved results of laryngoscope exams. RSI and RFS scores before and after PPI treatment reached statistical signification by paired t-test (t= 8.152, P<0.01; t=9.704, P<0.01). 21 patients' pepsin concentrations decreased except 5. Nonparametric tests were used because the reduction of pepsin concentrations before and after PPI treatment were not normally distributed (Z=-3.213, P<0.01). Reductions of total RSI and RFS scores as well as pepsin concentrations were significantly higher after two months. CONCLUSION Twice-daily PPI treatment for two months demonstrated a significantly greater improvement in laryngeal appearance and LPR symptoms for most patients in this study, which can result in significantly decreased levels of pepsin in sputum.
Adolescent ; Adult ; Esomeprazole ; therapeutic use ; Female ; Humans ; Laryngopharyngeal Reflux ; drug therapy ; metabolism ; Male ; Middle Aged ; Pepsin A ; metabolism ; Prospective Studies ; Proton Pump Inhibitors ; therapeutic use ; Sputum ; chemistry ; Treatment Outcome ; Young Adult

Adult ; Drug Therapy, Combination ; Female ; Humans ; Laryngopharyngeal Reflux ; drug therapy ; Male ; Middle Aged ; Treatment Outcome ; Young Adult

OBJECTIVETo explore the diagnostic values of 24-hour pH monitoring in patients with laryngopharyngeal reflux disease (LPRD).

METHODSFifty patients with suspected laryngopharyngeal reflux were enrolled into this study. Twenty five patients had 24-hour pH monitoring, antacid treatment with omeprazole was given in study group with pathologic reflux. The remaining 25 patients as control group only had the same antacid treatment. All the patients had 3 months follow up, and treatment effect was evaluated according to clinical manifestation improvement. After 3 month treatment followed up, it was defined as inefficacy treatment if the clinical manifestation score decrease was equal or less than 4, defined as efficacy if the score decrease was more than 4.

RESULTSSeventeen of 25 patients had pathologic reflux, positive rate was 68.0%. The mean times of total acid reflux was 35.71 +/- 41.70 (x +/- s), the mean total reflux time was (35.71 +/- 33.19) min, the mean total reflux index (reflux times per hour) was (1.53 +/- 1.73)/h, the mean reflux time was (1.12 +/- 0.91) min. Before antacid treatment, the mean clinical manifestation score was 14. 88 +/- 4.11 in study group and 13.00 +/- 4.17 in control group. There was no significant difference between the two groups (t = 1.444, P > 0.05). The validity of study group was 82.4% (14/17), Among the control group, two cases were out of followed, and the validity of remained patients was 52. 2% (12/23). The mean decreased score of clinical manifestation in study group was 7.47 +/- 3.18 and 3.96 +/- 4.25 in control group. There was significant difference between the two groups (t = 2. 864, P = 0.007).

CONCLUSIONSThe dual-probe 24-hour pH monitoring is considered the gold standard for diagnosis of LPRD and it is essential in patients who have laryngopharyngeal complaints and is capable to improve the effect of antacid treatment significantly. It's worthy of clinical application.

Adult ; Aged ; Antacids ; therapeutic use ; Esophageal pH Monitoring ; Female ; Humans ; Laryngopharyngeal Reflux ; diagnosis ; drug therapy ; physiopathology ; Male ; Middle Aged ; Omeprazole ; therapeutic use ; Pharynx ; physiopathology ; Young Adult